Ruti Aga's Six-Year Ban: Two Years for the Injection, Four for the Prescription Pad

Six years is not a number. It is a sum of two numbers. Take apart the sanction the Athletics Integrity Unit (AIU) announced on Thursday against Ruti Aga: two years for the positive sample collected after she won a half marathon in China in March, and four years for the document produced to explain that sample. Two years for the drug. Four for the prescription pad. Two-thirds of the ban sits on something that was never generated in a real clinic, never written by a registered doctor, and which its author admitted was written on “an old prescription pad from a former workplace” — a clinic that has since publicly disowned any connection to it. This is not a doping case. It is a document-management case. Which is why it should be read like a split table rather than a result: what changed at each quarter, and why. Aga is 32, an Ethiopian marathoner whose record is not trivial. She won the 2026 Tokyo Marathon and has three runner-up finishes at World Marathon Majors. My own notes carry Berlin 2026 in 2:18:34 for second and Tokyo 2026 in 2:20:40 for first — those marks are not in the AIU statement, so treat them as external record, not as quotation. That gap is itself the story: the statement contains no personal best, no time for the March race, no field strength, no splits. The March race was a half marathon in China that she won — that is all the statement says. It does not even state the year. That omission matters, because without the year you cannot fix which season the ban attaches to, which ranking points are voided, or what happens to that race's prize money. What the statement does say is clear: the sample was in-competition, meaning the race sat at World Athletics Label level with AIU testing present. What it does not say is equally clear — the scope of disqualification. Standard practice is that the competition at which the sample was collected is automatically annulled, with prize money; here it is unmentioned. In reporting, what goes unsaid is also news. It would be a mistake to read this case apart from the Chinese half-marathon circuit. For East African marathoners that circuit is an income tier between Majors: good appearance fees, low race counts, low apparent risk. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races, and Aga's file is the paper record of that collision. Now the part the media got wrong. Calling methylprednisolone a “prohibited steroid” and describing it as performance-enhancing is technically incorrect. It is a glucocorticoid, WADA Prohibited List class S9 — not an anabolic steroid (S1). And the S9 condition is specific: prohibited in-competition only, and only by injection, oral or rectal route. The consequence is that this case never hinged on “steroid use.” It hinged on route and timing. A therapeutic knee injection out of competition is entirely lawful; it becomes a violation only if residues are present in competition. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. This is where the case turns tragic. Aga had a legitimate defence available: genuine medical records for the knee injury, the injection date, an explanation of route and timing, and a Therapeutic Use Exemption application if required. A competent defence would have built a no-fault or no-significant-fault argument on exactly those facts, and the sanction could have collapsed to a reprimand. The best case was no case at all — a TUE-consistent treatment plan with correct washout timing. She did the opposite. The prescription was forged. And the moment it was forged, the only defence that could have worked was destroyed. It is the equivalent of being in front with 200 metres to go and stepping out of your lane to disqualify yourself. Three independent verification checks failed on that forged prescription, and they are the real evidence here. First, the clinic named on the document did not exist. Second, the person who wrote it held no medical registration — he was a family member. Third, the clinic whose “old pad” he invoked publicly disowned it. Not one check passed. This is not a filing error; it is the signature of an athlete operating without a credentialed team physician. And the knee, which is the entry point of the whole case, deserves a pause. Chronic knee pathology is a known load-bearing failure in high-volume marathoners, and intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice. That clinical plausibility is what makes the file bitter — if the treatment had genuinely happened and been documented, it would have been defended with real records. Prescriptions get forged when real paper does not exist. And the reason real paper does not exist is systemic: in East African distance-running camps, post-race treatment often runs through informal networks, TUE infrastructure is absent, and the pressure to mask pain is welded to the pressure to protect appearance-fee income. A glucocorticoid is the cheapest, most available tool for that. The sanction arithmetic fits that reading. Two years for presence is the level of sanction that follows a Specified Substance finding without proven intent. Four years for tampering is the Code's standard sanction. The sum is six. The sum also tells you the panel rejected the no-significant-fault mitigation that would otherwise have reduced the presence sanction. One fine paradox is worth noting: a forged prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction — it took its own charge instead. Backdating the ban to 10 September is procedure, not relief; provisional suspension time counts against the ban, and the athlete gains nothing in real terms. In career terms, the file is closed. At 32, a six-year ban makes the return age roughly 38. Ethiopia's women's marathon depth is such that even a 2:18 performer is not automatically selectable, so a 38-year-old returnee with a doping record is functionally unselectable. The ban is six years on paper and a career on the ground. What survives is the 2026 Tokyo title and three Major runner-up finishes, because the violation attaches to a later race and the statement announces no annulment of earlier results. Here is an uncomfortable point. Six years has been imposed for a substance with no proven endurance benefit. A glucocorticoid reduces pain and swelling; it does not improve a 400m split. So the real question in this file is not whether she gained an advantage, but whether she fabricated a document — and that is precisely what shows the enforcement frontier moving. The frontier has shifted from detection to document verification. Aga's case is not an outlier; it belongs to a recognisable family of East African road-racing files where the first violation is the substance and the second, heavier one is the fabricated explanation. A line on the media. The report that called methylprednisolone a “steroid” delivered the verdict before the panel did. That is the same class of error as printing a wrong mark, and for me it is personal. At seventeen, calling the Ahmedabad district schools 200m final, I mispronounced one sprinter's name three times; I built a phonetic card for every athlete after that, because three mispronounced names taught me that a microphone is a responsibility before it is a voice. Misstating a substance class is that same responsibility. And here the error had a double cost: the public lost the only genuinely interesting legal question in the case — the question of route and timing, on which a defence could have stood. But sympathy must not be allowed to become absolution. Three verification checks failed, a family member wrote the prescription, the clinic did not exist, and the four-year tampering sanction rests on statements given in an AIU interview — meaning the account was fabricated as well as the document. Let that stay on the record, asterisk attached. It also bears saying that AIU interviews are conducted in English and that translation conditions have been a recurring point of contention for East African athletes; language deserves the same seriousness we give to names. And register one silence: the statement carries no response from the Ethiopian national federation. Only the AIU has spoken. What to watch next is clear. A CAS appeal window of roughly 21 days opens from the reasoned decision; document-based findings rarely overturn, but the window is real. The disqualification scope is undeclared — the March result, its prize money and subsequent ranking points all await a ruling. And most importantly, whether the agent or management was investigated is nowhere in the statement, even though someone accepted or suggested that document. Until that question is answered, Aga's case will remain the story of a structure rather than the story of a runner. The question is not whether six years is too much or too little. It is whether the next athlete who needs a knee injection will have a documented route to telling the truth, or just one more old prescription pad.